全球小分子 CDMO 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测
市场调查报告书
商品编码
1408967

全球小分子 CDMO 市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Small Molecule CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: | 出版商: Value Market Research | 英文 234 Pages | 商品交期: 最快1-2个工作天内

价格

全球小分子 CDMO 市场需求预计将从 2023 年的 682.3 亿美元增加到 2032 年的近 1,379.8 亿美元,2024-2032 年研究期间复合CAGR为 8.14%。

小分子合约开发和製造组织 (CDMO) 是提供与小分子药物的开发、製造(有时包括测试)相关服务的公司。小分子通常是在药物製剂中用作活性药物成分的低分子量化合物。 CDMO 代表製药和生技公司提供生产这些小分子药物的专业知识和基础设施。

市场动态

小分子合约开发和製造组织 (CDMO) 市场受到反映製药业不断变化的格局的几个因素的推动。在对成本效率和专业知识的渴望的推动下,药物开发和製造的外包趋势不断增加,这大大增加了对小分子 CDMO 服务的需求。小分子药物开发的复杂性日益增加,加上药物管道的增加,促使製药公司寻求外部合作伙伴来进行化学合成、製程优化和监管合规。专注于核心能力、具成本效益的解决方案和药品製造的全球化进一步推动市场。小分子 CDMO 提供灵活性、可扩展性和加速上市时间,吸引了希望有效应对药物开发复杂阶段的公司。技术进步和 CDMO 的监管专业知识也发挥关键作用,确保客户能够获得最先进的解决方案并能够无缝满足监管要求。随着製药业的不断发展,小分子 CDMO 市场预计将持续成长,从而塑造药物开发和製造合作伙伴关係的格局。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外,这些工具也对全球小分子 cdmo 市场的各个细分市场进行了包容性评估。小分子 cdmo 产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景,重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲小分子 CDMO 市场当前和未来的需求。此外,该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。小分子CDMO市场的主要参与者包括Lonza、Catalent, Inc.、Thermo Fisher Scientific Inc.、Cambrex Corporation、Bellen Chemistry、Siegfried Holding AG、Recipharm AB、Eurofins Scientific、Aurigene Pharmaceutical Services Ltd.、CordenPharma International。本节包含竞争格局的整体视图,包括各种策略发展,例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求,请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章:前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法论
    • 市场研究过程
    • 市场研究方法论

第 2 章:执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章:小分子 CDMO - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按产品分類的市场吸引力分析
    • 按药物类型分類的市场吸引力分析
    • 市场吸引力分析:依应用分类
    • 市场吸引力分析:按地区

第 4 章:价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章:全球小分子 CDMO 市场分析:依产品分类

  • 按产品概述
  • 历史和预测数据
  • 按产品分析
  • 活性药物成分 (API)
  • 药品成品

第 6 章:全球小分子 CDMO 市场分析:依药物类型

  • 按药物类型概述
  • 历史和预测数据
  • 依药物类型分析
  • 创新者
  • 泛型

第 7 章:全球小分子 CDMO 市场分析:依应用分类

  • 概述:按应用
  • 历史和预测数据
  • 分析:按应用
  • 肿瘤学
  • 心血管疾病
  • 中枢神经系统 (CNS) 状况
  • 自体免疫/炎症
  • 其他的

第 8 章:全球小分子 CDMO 市场分析:依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 9 章:小分子 CDMO 公司的竞争格局

  • 小分子Cdmo市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 10 章:公司简介

  • 公司股份分析
  • 市场集中度
  • Lonza
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Catalent Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Thermo Fisher Scientific Inc.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Cambrex Corporation
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Bellen Chemistry
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Siegfried Holding AG
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Recipharm AB
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Eurofins Scientific
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • Aurigene Pharmaceutical Services Ltd.
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展
  • CordenPharma International
    • 公司简介
    • 公司收入
    • 产品
    • 最近的发展

注意 - 在公司概况中,财务详细资讯和近期发展视情况而定,或者如果是私人公司,则可能不包括在内

Product Code: VMR112113289

The global demand for Small Molecule CDMO Market is presumed to reach the market size of nearly USD 137.98 BN by 2032 from USD 68.23 BN in 2023 with a CAGR of 8.14% under the study period 2024 - 2032.

Small Molecule Contract Development and Manufacturing Organizations (CDMOs) are companies that provide services related to the development, manufacturing, and sometimes testing of small molecule drugs. Small molecules are typically low molecular weight compounds that are used as active pharmaceutical ingredients in drug formulations. CDMOs offer expertise and infrastructure for the production of these small molecule drugs on behalf of pharmaceutical and biotechnology companies.

MARKET DYNAMICS

The Small Molecule Contract Development and Manufacturing Organization (CDMO) market is propelled by several factors reflecting the evolving landscape of the pharmaceutical industry. Increasing outsourcing trends in drug development and manufacturing, driven by a desire for cost efficiency and specialized expertise, contribute significantly to the demand for Small molecule CDMO services. The growing complexity of small molecule drug development, coupled with the rise in drug pipelines, prompts pharmaceutical companies to seek external partners for chemical synthesis, process optimization, and regulatory compliance. Focus on core competencies, cost-effective solutions, and the globalization of pharmaceutical manufacturing further fuel the market. Small molecule CDMOs offer flexibility, scalability, and accelerated time-to-market, attracting companies looking to navigate the intricate stages of drug development efficiently. Technological advancements and the CDMOs' regulatory expertise also play pivotal roles, ensuring clients have access to state-of-the-art solutions and can navigate regulatory requirements seamlessly. As the pharmaceutical industry continues to evolve, the Small molecule CDMO market is expected to witness sustained growth, shaping the landscape of drug development and manufacturing partnerships.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule cdmo. The growth and trends of small molecule cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Active Pharmaceutical Ingredients (API)
  • Finished Drug Products

By Drug Type

  • Innovators
  • Generics

By Application

  • Oncology
  • Cardiovascular Disease
  • Central Nervous System (Cns) Conditions
  • Autoimmune/Inflammation
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule CDMO market include Lonza, Catalent, Inc., Thermo Fisher Scientific Inc., Cambrex Corporation, Bellen Chemistry, Siegfried Holding AG, Recipharm AB, Eurofins Scientific, Aurigene Pharmaceutical Services Ltd., CordenPharma International. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . SMALL MOLECULE CDMO - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Drug Type
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY PRODUCT

  • 5.1 Overview by Product
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Product
  • 5.4 Active Pharmaceutical Ingredients (API) Historic and Forecast Sales by Regions
  • 5.5 Finished Drug Products Historic and Forecast Sales by Regions

6 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY DRUG TYPE

  • 6.1 Overview by Drug Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Drug Type
  • 6.4 Innovators Historic and Forecast Sales by Regions
  • 6.5 Generics Historic and Forecast Sales by Regions

7 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Oncology Historic and Forecast Sales by Regions
  • 7.5 Cardiovascular Disease Historic and Forecast Sales by Regions
  • 7.6 Central Nervous System (CNS) Conditions Historic and Forecast Sales by Regions
  • 7.7 Autoimmune/Inflammation Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL SMALL MOLECULE CDMO MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE CDMO COMPANIES

  • 9.1. Small Molecule Cdmo Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF SMALL MOLECULE CDMO INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. Lonza
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Catalent Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Thermo Fisher Scientific Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Cambrex Corporation
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Bellen Chemistry
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Siegfried Holding AG
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Recipharm AB
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Eurofins Scientific
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Aurigene Pharmaceutical Services Ltd.
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. CordenPharma International
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Product (USD MN)
  • Active Pharmaceutical Ingredients (API) Market Sales by Geography (USD MN)
  • Finished Drug Products Market Sales by Geography (USD MN)
  • Analysis Market by Drug Type (USD MN)
  • Innovators Market Sales by Geography (USD MN)
  • Generics Market Sales by Geography (USD MN)
  • Analysis by Application (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Central Nervous System (CNS) Conditions Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Small Molecule Cdmo Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Small Molecule Cdmo Report
  • Market Research Process
  • Market Research Methodology
  • Global Small Molecule Cdmo Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Product
  • Market Attractiveness Analysis by Drug Type
  • Market Attractiveness Analysis by Application
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Product (USD MN)
  • Active Pharmaceutical Ingredients (API) Market Sales by Geography (USD MN)
  • Finished Drug Products Market Sales by Geography (USD MN)
  • Global Market Analysis by Drug Type (USD MN)
  • Innovators Market Sales by Geography (USD MN)
  • Generics Market Sales by Geography (USD MN)
  • Global Market Analysis by Application (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Central Nervous System (CNS) Conditions Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.